dc.description.abstract | The aim of the present study determines the effect of zinc and melatonin supplementation on IL-6
levels in female rats with breast cancer induced by DMBA (7,12-Dimethylbenz[a]anthracene). Total 42 wistar
female rats which was just weaned from milk equally separated 5 groups. Group 1 control, Group 2 DMBA
control, Group 3 DMBA+Zinc, Group 4 DMBA+Melatonin, Group 5 DMBA+Zinc+Melatonin. To induce
breast cancer, the animals, except those in group 1, were administered 80 mg/kg of DMBA in colza oil (canola)
through gavage. The groups which were supplemented with zinc and melatonin were introperitoneally given 5
mg/kg/day of zinc, melatonin and zinc+melatonin for 4 weeks. Blood samples were taken under general
anesthesia to tube with EDTA, and IL-6 levels were determined by ELISA. The highest IL-6 levels were
determined in the DMDA control group (p<0.05). DMBA + zinc and DMBA+ melatonin groups were had lower
IL-6 levels compared to group 2 (p<0.05). Group 5 has the lowest IL-6 levels compared to all breast cancer
induced groups (G 2,3,4) (p<0.05). The results of the present study indicate that increased IL-6 levels in breast
cancer inhibites by zinc and melatonin. However, the most significant inhibition was seen in combine of zinc
and melatonin (group 5). The combined administration of zinc + melatonin may contribute to the prevention of
tumoral growth by suppressing IL-6 levels, which can accelerate cancer development. | en_US |